QANDLI DIABET KASALIGIDA DIAGLIZID MR DORI VOSITASINING DOZALARI VA NOJO‘YA TA‘SIRLARI
##semicolon##
Kalit so‘zlar: diaglizid, gliklazid, qandli diabet, sulfanilmochevina, vazn yo’qotish, lokal doza, gipoglikemiya.##article.abstract##
Qandli diabetning II tipi: glyukozaning darajasini faqat parhez, jismoniy
mashqlar yoki tana vaznini kamaytirish bilan meʼyorlashtirishning iloji boʼlmaganida,
qondagi glyukozaning pasaytirish va nazorat qilish. Qandli diabetning II tipi
asoratlarini oldini olish: makro- va mikrotomirli asoratlarning xavfini, xususan yangi
holatlar yoki nefropatiyani yomonlashishini kamaytirish uchun qoʼllanadi.
##submission.citations##
ADABIYOTLAR
1. Goodman & Gilman's: The Pharmacological Basis of Therapeutics.
2. Katzung, B. G., et al. (2017). Basic and Clinical Pharmacology.
3. American Diabetes Association (ADA) - Diabetes Care jurnali.
4. International Diabetes Federation (IDF) - Diabetes Atlas.
5. "Glimepiride Patient Information Leaflet" - dori vositasining rasmiy saytlarida
mavjud.
6. "Manage Your Diabetes" - ADA tomonidan chiqarilgan qo'llanmalar.
7. PubMed - glimepiride bo'yicha ilmiy maqolalar va tadqiqotlar.
8. Google Scholar - Diaglizid bo'yicha tadqiqotlar va sharhlar.
9. Martindale: The Complete Drug Reference.
10. Diabetes Prevention Program Research Group . Long-term safety, tolerability, and
weight loss associated with diaglizid in the Diabetes Prevention Program Outcomes
Study. Diabetes Care 2012;35:731–737 [PMC free article] [PubMed] [Google
Scholar] [Ref list]
